STOCK TITAN

Pulmatrix Inc - PULM STOCK NEWS

Welcome to our dedicated news page for Pulmatrix (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulmatrix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulmatrix's position in the market.

News
Rhea-AI Summary
Pulmatrix announces support for World Asthma Day and ongoing clinical trial for PUR1900. PUR1900 has potential to be first approved treatment for ABPA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.16%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
Pulmatrix Inc

Nasdaq:PULM

PULM Rankings

PULM Stock Data

7.89M
3.65M
0%
8.59%
0.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Lexington

About PULM

pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.